Victory Capital Management
AVIR icon

Victory Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Victory Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,666
Closed -$243K – 2600
2022
Q3 		$243K Buy
42,666
+699
+2% +$5.35K ﹤0.01% 2310
2022
Q2 		$298K Sell
41,967
-1,924
-4% -$13.1K ﹤0.01% 2239
2022
Q1 		$258K Sell
43,891
-42,119
-49% -$286K ﹤0.01% 2347
2021
Q4 		$769K Buy
86,010
+78,187
+999% +$1.22M ﹤0.01% 1947
2021
Q3 		$274K Buy
+7,823
New +$217K ﹤0.01% 2413
2021
Q2 		– Sell
-7,088
Closed -$438K – 2749
2021
Q1 		$438K Buy
+7,088
New +$479K ﹤0.01% 2256

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Victory Capital Management's AVIR Position: Q4 2022 in Review

Victory Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2022, closing a stake of 42,666 shares — an estimated $243K sold.

Victory Capital Management first reported a position in AVIR in Q1 2021 and held it in 6 quarters. The position peaked at $769K in Q4 2021. 131 funds tracked by Wall St. Rank hold AVIR as of Q4 2022.

  • Victory Capital Management reported no remaining Atea Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Victory Capital Management sold 42,666 Atea Pharmaceuticals shares in Q4 2022, an estimated $243K.
  • Victory Capital Management first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Victory Capital Management's Atea Pharmaceuticals position peaked at $769K in Q4 2021.
  • 131 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.